PDLIM7 and nasopharyngeal carcinoma: The utility of LMP1-targeted DNAzyme as a systemic treatment for NPC patients, especially with advanced disease, needs to be further elucidated using efficient in vivo delivery vehicles, such as nanoparticles (90).